NASDAQ
10.59USD
+0.01 (+0.09%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
775.9M
P/E
—
EPS
—
Beta
-0.50
52W range
4.35-11.36
Day range
10.52–10.74
Open
10.69
Prev close
10.58
Volume
800.8K
Avg volume
1.9M
Dividend
0.00
IPO
2021-07-27
https://www.businesswire.com/news/home/20260810907136/en/Cadeler-Strengthens-Future-Installation-Capacity-With-Firm-Orders-for-Two-New-T-class-Vessels/ · 8/10/2026+0.60
https://seekingalpha.com/article/4919788-candel-therapeutics-an-overlooked-late-stage-biotech-with-real-potential · 7/4/2026+0.80
https://www.zacks.com/stock/news/2923363/wall-street-analysts-believe-candel-therapeutics-cadl-could-rally-148-48-here-s-is-how-to-trade?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2923363 · 5/19/2026+0.80
https://seekingalpha.com/article/4905396-candel-therapeutics-inc-cadl-discusses-extended-follow-up-data-from-phase-3-trial-of · 5/16/2026+0.60
https://www.globenewswire.com/news-release/2026/05/15/3296125/0/en/Candel-Therapeutics-Reports-Extended-Clinical-Benefit-Over-Multiple-Clinical-Endpoints-in-Patients-from-Phase-3-Trial-of-Aglatimagene-Besadenovec-CAN-2409-in-Localized-Prostate-Can.html · 5/15/2026+1.00
https://www.defenseworld.net/2026/03/21/candel-therapeutics-inc-nasdaqcadl-receives-18-00-average-target-price-from-brokerages.html · 3/21/2026+0.60
https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-130-million-in-growth-capital-to-candel-therapeutics-supporting-development-of-viral-immunotherapies-to-fight-cancer-302582805.html · 10/14/2025+0.90
https://seekingalpha.com/article/4829505-candel-therapeutics-has-a-protracted-but-real-timeline-to-approval-now · 10/13/2025+0.20
https://www.globenewswire.com/news-release/2025/08/28/3140766/0/en/Candel-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences-in-September.html · 8/28/2025+0.20
https://www.proactiveinvestors.com/companies/news/1076801 · 8/16/2025+1.00
https://www.proactiveinvestors.com/companies/news/1076700 · 8/14/2025+1.00
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
